Equities Analysts Offer Predictions for Poseida Therapeutics

Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) – Investment analysts at HC Wainwright upped their Q2 2024 EPS estimates for Poseida Therapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst A. He now anticipates that the company will earn ($0.43) per share for the quarter, up from […]

Related Keywords

, Tower Research Capital , Poseida Therapeutics Inc , Nasdaq , Poseida Therapeutics Company Profile , Dynamic Technology Lab Private Ltd , Keystone Financial Group , Allspring Global Investments Holdings , Poseida Therapeutics , Free Report , Poseida Therapeutic , Get Free Report , Global Investments Holdings , Capital Management , Technology Lab Private Ltd , Research Capital , Heme Malignancies , Poseida Therapeutics Daily ,